Literature DB >> 23994575

NLRP3 inflammasome activation in D-galactosamine and lipopolysaccharide-induced acute liver failure: role of heme oxygenase-1.

Seok-Joo Kim1, Sun-Mee Lee2.   

Abstract

D-Galactosamine (GalN) and lipopolysaccharide (LPS) are commonly used to study mechanisms of hepatic malfunction that result in hepatic inflammation and subsequent fulminant hepatic failure. Inflammasomes are intracellular multiprotein complexes that in response to cellular danger signals trigger the biological maturation of proinflammatory cytokines. Heme oxygenase-1 (HO-1) is a cytoprotective enzyme that induces anti-inflammatory and antioxidant activity against oxidative cellular stress. This study examined activation of the NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome in GalN/LPS-induced hepatic injury and the role of HO-1 in the signaling pathways of inflammasome. Mice (C57BL/6) were pretreated twice with hemin (HO-1 inducer, 30 mg/kg) and zinc protoporphyrin (ZnPP; HO-1 inhibitor, 10mg/kg) at 12 and 2h before GalN (800 mg/kg)/LPS (40 μg/kg) administration. HO-1 induction with hemin reversed the lethality induced by GalN/LPS administration, and ZnPP pretreatment blocked this change. Lipid peroxidation markedly increased after GalN/LPS treatment, whereas glutathione content decreased in the GalN/LPS group. These changes were attenuated by hemin, but ZnPP reversed the effects of hemin. Serum levels of tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β increased after GalN/LPS treatment; these increases were attenuated by hemin. Hepatic mRNA levels of TNF-α, IL-1β, and NLRP3 increased after GalN/LPS treatment, and hemin attenuated increases in TNF-α and IL-1β. After GalN/LPS treatment, the hepatic expression of NLRP3, ASC, and caspase-1 (p10) was increased. In immunoprecipitation studies, hemin attenuated the interaction of NLRP3 with ASC and caspase-1. GalN/LPS induced expression of the thioredoxin-interacting protein (TXNIP) gene and the interaction between NLRP3 and TXNIP; again, hemin attenuated these effects. The effects of hemin were reversed by ZnPP. Our findings suggest that activation of the NLRP3 inflammasome leads to a GalN/LPS-induced inflammatory response through TXNIP-NLRP3 interaction. Furthermore, HO-1 overexpression may protect the liver against GalN/LPS-induced inflammation through suppression of the NLRP3 signaling pathway.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASC; Acute liver failure; Free radicals; GSH; GSSG; GalN; HO; Heme oxygenase-1; IL; Interleukin-1β; LPS; MDA; NACHT, LRR, and pyrin domain-containing protein 3; NF-κB; NLRP3; NLRP3 inflammasome; ROS; Reactive oxygen species; SDS; TLR; TNF; TRX; TXNIP; Toll-like receptor; ZnPP; apoptosis-associated speck-like protein containing a CARD; d-galactosamine; heme oxygenase; interleukin; lipopolysaccharide; malondialdehyde; nuclear factor κB; oxidized glutathione; reactive oxygen species; reduced glutathione; sodium dodecyl sulfate; thioredoxin; thioredoxin-interacting protein; tumor necrosis factor; zinc protoporphyrin

Mesh:

Substances:

Year:  2013        PMID: 23994575     DOI: 10.1016/j.freeradbiomed.2013.08.178

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  39 in total

Review 1.  The A to Z of modulated cell patterning by mammalian thioredoxin reductases.

Authors:  Markus Dagnell; Edward E Schmidt; Elias S J Arnér
Journal:  Free Radic Biol Med       Date:  2017-12-24       Impact factor: 7.376

2.  The protective effect of epigallocatechin 3-gallate on mouse pancreatic islets via the Nrf2 pathway.

Authors:  Yuma Wada; Atsushi Takata; Tetsuya Ikemoto; Yuji Morine; Satoru Imura; Shuichi Iwahashi; Yu Saito; Mitsuo Shimada
Journal:  Surg Today       Date:  2019-02-07       Impact factor: 2.549

Review 3.  Heme Oxygenases in Cardiovascular Health and Disease.

Authors:  Anita Ayer; Abolfazl Zarjou; Anupam Agarwal; Roland Stocker
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 4.  Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit.

Authors:  Islam N Mohamed; Tauheed Ishrat; Susan C Fagan; Azza B El-Remessy
Journal:  Antioxid Redox Signal       Date:  2014-11-11       Impact factor: 8.401

Review 5.  Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation.

Authors:  Stefan W Ryter; Augustine M K Choi
Journal:  Transl Res       Date:  2015-06-23       Impact factor: 7.012

6.  RORγ regulates the NLRP3 inflammasome.

Authors:  Cyrielle Billon; Meghan H Murray; Amer Avdagic; Thomas P Burris
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

7.  Hemin and Cobalt Protoporphyrin Inhibit NLRP3 Inflammasome Activation by Enhancing Autophagy: A Novel Mechanism of Inflammasome Regulation.

Authors:  Katariina Nurmi; Ilona Kareinen; Juhani Virkanen; Kristiina Rajamäki; Vesa-Petteri Kouri; Kirsi Vaali; Anna-Liisa Levonen; Nanna Fyhrquist; Sampsa Matikainen; Petri T Kovanen; Kari K Eklund
Journal:  J Innate Immun       Date:  2016-09-22       Impact factor: 7.349

8.  Human SR-BI and SR-BII Potentiate Lipopolysaccharide-Induced Inflammation and Acute Liver and Kidney Injury in Mice.

Authors:  Irina N Baranova; Ana C P Souza; Alexander V Bocharov; Tatyana G Vishnyakova; Xuzhen Hu; Boris L Vaisman; Marcelo J Amar; Zhigang Chen; Yana Kost; Alan T Remaley; Amy P Patterson; Peter S T Yuen; Robert A Star; Thomas L Eggerman
Journal:  J Immunol       Date:  2016-03-02       Impact factor: 5.422

9.  MicroRNA 223 3p Negatively Regulates the NLRP3 Inflammasome in Acute and Chronic Liver Injury.

Authors:  Carolina Jimenez Calvente; Hana Del Pilar; Masahiko Tameda; Casey D Johnson; Ariel E Feldstein
Journal:  Mol Ther       Date:  2019-09-13       Impact factor: 11.454

10.  Protective Effect of Astragaloside IV Against Paraquat-Induced Lung Injury in Mice by Suppressing Rho Signaling.

Authors:  Tong Chen; Ruoning Wang; Wenjiao Jiang; Huimin Wang; Ang Xu; Guo Lu; Yi Ren; Yangmei Xu; Yangyang Song; Shoulei Yong; Hui Ji; Zhanqiang Ma
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.